妊娠高血圧と妊娠高血圧腎症の腎機能の関係性について by Nobumoto, Etsuko
P regnancy-induced hypertension (PIH),  which is characterized by hypertension and proteinuria,  is 
a multifactor disorder and one of the main causes of 
perinatal and maternal morbidity and mortality [1].  
PIH complicates 3.0-4.6% of Japanese pregnancies [2].  
Gestational hypertension (GH) is thought to be differ-
ent from preeclampsia (PE) in many countries,  includ-
ing the United States and Canada,  according to The 
American Congress of Obstetricians and Gynecologists 
(http://www.acog.org/Resources-And-Publications/
Task-Force-and-Work-Group-Reports/ Hypertension-
in-Pregnancy; accessed June 1,  2016) and the Journal 
of Obstetrics and Gynecology Canada (http://sogc.org/
wp-content/uploads/2013/01/ui206CPG0803hyperten-
sioncorrection.pdf; accessed June 1,  2016).
However,  in Japan GH and PE are usually treated as 
the same disease (i.e.,  PIH).  GH/PE is classified as a 
sub-classification of PIH,  but GH and PE are treated 
basically as PIH with superimposed preeclampsia,  
eclampsia,  and management.  Methods and guidance 
specific to PE or GH are not used in Japan.  We con-
ducted the present study to determine whether there are 
any differences in perinatal outcomes,  fetal growth,  
and maternal kidney function between pregnancies 
with PE and those with GH in order to investigate the 
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Although gestational hypertension (GH) is thought to be different from preeclampsia (PE),  in Japan GH and PE 
are usually treated as the same disease (i.e.,  pregnancy-induced hypertension).  Here we sought to determine 
whether there are any differences in fetal growth and maternal kidney function between pregnancies with PE 
and those with GH.  We retrospectively analyzed 61 GH patients and 60 PE patients with singleton pregnancies 
who delivered at Okayama University Hospital (2008-2015).  We compared maternal and perinatal outcomes 
and maternal kidney function parameters between the GH and PE pregnancies.  The mean values of maternal 
age (p= 0.01),  gestational age at delivery (p< 0.0001),  placental weight (p= 0.002),  birth weight and height 
(p< 0.0001,  p= 0.0001),  and head circumference standard deviation score (p= 0.007) of newborns of the GH 
group were significantly higher than those of the PE group.  The duration until termination of PE or GH was not 
significantly correlated with kidney function.  The birth weight percentile was significantly correlated with kid-
ney function in PE but not GH.  However,  GH patients with poor kidney function and small-for-gestational age 
infants showed perinatal outcomes similar to those of the PE group.  Monitoring kidney function is thus 
important for determining the severity of PE and GH.
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necessity of different treatments between PE and GH.
Materials and Methods
In this retrospective,  cross-sectional study,  we ret-
rospectively analyzed the cases of 61 patients with GH 
and 60 patients with PE who had a singleton pregnancy 
and delivered at Okayama University Hospital between 
2008 and 2015.  We compared perinatal outcomes,  fetal 
growth,  and maternal kidney function in the GH and 
PE cases.
GH was defined as the presence of hypertension 
(blood pressure ≥ 140/90 mmHg) without proteinuria 
(we confirmed that there was no proteinuria until deliv-
ery) after the 20th week of gestation.  Preeclampsia was 
defined as hypertension (blood pressure ≥140/90 mmHg) 
and proteinuria (proteinuria ≥ 300 mg/day) after the 
20th week of gestation.  The definition of ‘severe GH’ 
was blood pressure ≥ 160/110 mmHg.  Cases that 
involved eclampsia or superimposed PE were excluded 
from the study.  The above-mentioned criteria were 
issued by the Japan Society for the Study of Hyper-
tension in Pregnancy [3].
We collected data regarding both maternal and peri-
natal characteristics.  The delivery data also included 
those for artificial termination,  membrane rupture,  
and natural labor pains.  We excluded the cesarean sec-
tion after labor pains and uterus operation from the 
emergency cesarean section.  We identified the birth 
weight percentile,  birth height percentile,  and head 
circumference percentile in each case and compared 
them with the Japanese standards [4].  ‘Small for gesta-
tional age (SGA)’ was defined as less than the 10th per-
centile for birth weight.  The duration until termination 
was the length from the onset of PE or GH to delivery.
Blood samples were collected ≤ 1 week before deliv-
ery.  Serum uric acid (UA) (Sino-test,  Tokyo) and cre-
atinine (Mizuho Medical,  Saga,  Japan) levels were 
measured using enzymatic methods [5].  High UA levels 
were defined as > 5.6 mg/dl and normal UA levels as 
< 5.5 mg/dl.  The estimated glomerular filtration rate 
(eGFR) was calculated using serum creatinine levels 
(eGFR for Japanese) [6].  We omitted data that were 
collected > 1 week before delivery.  The median (range) 
time that blood samples were collected was 1 day (0-6 
days) before delivery for GH and 0 days (0-7 days) 
before delivery for PE.
We used Microsoft Excel 2010 for Windows 7 for the 
statistical analysis.  Maternal and perinatal outcomes 
were compared using the Mann-Whitney U-test.  The 
statistical significance of complications between the GH 
and PE groups was determined by the χ2 test.  We per-
formed a Pearson’s correlation coefficient test to com-
pare the maternal kidney function with weeks of onset 
and fetal growth,  and to examine the correlations 
between UA levels,  creatinine levels,  and eGFR.  Values 
of p < 0.05 were considered significant.  The study proto-
col was approved by the Ethics Committee at Okayama 
University Hospital (1606-516).
Results
The maternal characteristics,  kidney function,  and 
perinatal outcomes in the GH and PE groups are sum-
marized in Table 1.  The gestational age at diagnosis and 
at admission in the women with PE were significantly 
earlier than those in the women with GH.  In the GH 
group,  the maternal age was significantly higher 
(p = 0.01),  the gestational age at delivery was signifi-
cantly greater (p < 0.0001),  the placental weight was 
significantly heavier (p < 0.002),  and the birth weight 
(p < 0.0001),  birth height (p = 0.0001),  and head cir-
cumference standard deviation score of the newborns 
were significantly greater (p < 0.005) compared to the 
corresponding values in the PE group.  Significantly 
more patients with PE had high blood pressure than 
those with GH (p = 0.0007).
In the GH group,  the maternal weight,  body mass 
index (BMI) before pregnancy,  and UA levels were 
higher than those in the PE group,  but these differences 
were not significant.  There were no significant 
between-group differences in weight gain during preg-
nancy,  the rate of previous PIH,  the rate of primipara,  
the Apgar scores,  the pH of the umbilical artery,  blood 
loss,  platelets,  creatinine levels,  eGFR,  or maternal 
complications including diabetes mellitus,  collagen dis-
ease,  and antiphospholipid antibody syndrome.  
Gestational diabetes mellitus (GDM) was significantly 
more common among the patients with GH compared 
to those with PE.
We also analyzed the platelets,  antithrombin III lev-
els,  D-dimer levels,  and hematocrit (in the patients for 
whom these data were available; Table 1),  and no sig-
nificant differences between the groups were revealed.  
Previous miscarriage and stillbirth occurred in 11 of 38 
(29%) GH patients and 17 of 31 (55%) PE patients,  with 
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significant differences between the groups (p = 0.03).  A 
previous arrest of fetal growth occurred in 2 of 38 cases 
of GH and 3 of 31 cases of PE,  with no significant dif-
ferences between the groups (p = 0.5).
The rate of use of antihypertensive medicine was 
30% in the GH group and 72% in the PE group.  The 
time point of starting antihypertensive medicine was a 
median (range) of 0 weeks (0-2 weeks) before delivery 
in the GH group and 1 week (1-12 weeks) before deliv-
ery in the PE group.  The rate of the use of low-dose 
aspirin in the first trimester prescribed due to antiphos-
pholipid antibody syndrome was 8.3% in the PE group 
versus 11.4% in the GH group,  with the exception of 
one GH patient who took medicine for high blood pres-
sure from the 26th gestational week (data not shown).
We analyzed the correlation between maternal kid-
ney function parameters and fetal growth.  The correla-
tions between birth weight percentile and maternal 
kidney function parameters were significant in the PE 
group (UA: r = −0.54 p < 0.0001; creatinine: r = −0.47,  
p = 0.0001; eGFR: r = 0.37,  p = 0.003),  but these were 
not significant in the GH group (UA: r = −0.16,  
p=0.25; creatinine: r=−0.01,  p=0.92; eGFR: r=0.08,  
p = 0.52) (Fig. 1).  The correlations of maternal kidney 
function parameters with birth height percentile and 
head circumference were not significant in either group 
(data not shown).
We also analyzed the associations between kidney 
function parameters and mild and severe hypertension 
in the GH and PE groups.  As shown in Table 2,  the UA 
levels were significantly different (p = 0.03) between the 
patients with severe hypertension and those with mild 
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Table 1　 Maternal and perinatal characteristics and maternal kidney function in the preeclampsia (PE) and gestational hypertension 
(GH) groups
GH (n＝61) PE (n＝60) p
Maternal age (yrs) 34±5.3 32±5.9 0.01
Weight of pre-pregnancy (kg) 62.2±16.0 57.6±15.3 NS
BMI before pregnancy (kg/m2) 24.6±5.5 23.4±5.8 NS
Gestational weight gain (kg) 8.8±5.7 9.6±5.1 NS
Gestational age at delivery (wks) 37.8±2.1 35.5±3.4 ＜0.0001
Ratio of PIH in the past for multipara (%) 13 19 NS
Gestational age at diagnosis of GH or PE 35±5.3 33±4.9 0.01
Gestational age at admission 37±2.5 34±4.1 ＜0.0001
Placental weight (g) 506±132 434±128 0.002
Ratio of primipara (%) 64 73 NS
Infant birth weight (g) 2,657±618 2,105±763 ＜0.0001
Infant birth weight (primipara) (g) 2,675±590 2,151±770 0.0009
Infant birth weight (multipara) (g) 2,618±691 2,019±765 0.01
Infant birth weight percentile 39.2±31.9 22.7±26.0 0.002
Infant birth height (cm) 48±3.5 44±5.3 0.0001
Infant birth height percentile 55.0±31.6 39.8±30.9 0.008
Head circumference percentile 49.3±29.5 35.9±24.3 0.007
Circumference of the chest/head 0.91±0.06 0.87±0.08 0.03
UmApH 7.29±0.09 7.27±0.08 NS
Apgar score (1 min) 7.6±1.7 7.4±1.7 NS
Apgar score (5 min) 8.7±1.3 8.5±1.4 NS
Ratio of severe blood pressure (%) 36 67 0.0007
Serum albumin (g/ml) 3.0±0.3 2.6±0.4 ＜0.0001
UA (mg/dl) 5.76±1.66 (n＝50) 6.49±1.95 (n＝53) NS
Creatinine (mg/dl) 0.63±0.18 (n＝49) 0.68±0.15 (n＝55) NS
eGFR(ml/min) 97.0±29.1 (n＝49) 88.9±27.0 (n＝56) NS
DM (types I or II) 4 3 NS
GDM 8 1 0.02
Collagen disease 0 2 NS
APS 7 5 NS
The data are mean ± SD.  NS,  not signiﬁcant; BMI,  body mass index; UmApH,  umbilical artery pH; UA,  uric acid; eGFR,  estimated 
glomerular ﬁltration rate; DM,  diabetes mellitus; GDM,  gestational diabetes mellitus; APS,  antiphospholipid antibody syndrome.
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Fig. 1　Correlations of maternal kidney function parameters and fetal growth in cases of preeclampsia and gestational hypertension.
Table 2　 Correlations of kidney function parameters with mild and severe hypertension in the gestational hypertension and preeclampsia 
groups and all patients
Severe hypertension Mild hypertension p
PE and GH
n＝121
n＝64 n＝57
UA (mg/dl) 6.54±1.82 5.76±1.79 0.03
Creatinine (mg/dl) 0.67±0.18 0.63±0.14 0.20
eGFR (ml/min) 86.4±26.0 90.9±26.9 0.45
PE
n＝60
n＝40 n＝20
UA (mg/dl) 6.79±1.83 5.92±2.10 0.12
Creatinine (mg/dl) 0.69±0.15 0.66±0.16 0.33
eGFR (ml/min) 84.3±21.0 88.8±24.2 0.51
GH
n＝61
n＝24 n＝37
UA (mg/dl) 6.10±1.76 5.66±1.59 0.37
Creatinine (mg/dl) 0.64±0.23 0.62±0.14 0.74
eGFR (ml/min) 91.9±35.9 92.5±29.3 0.95
PE,  preeclampsia; GH,  gestational hypertension; UA,  uric acid; eGFR,  estimated glomerular ﬁltration rate.
hypertension in the complete patient series,  but there 
were no significant differences within the PE or GH 
groups.  There were no significant correlations of blood 
pressure with creatinine levels or eGFR (Table 2).  Our 
analysis of the association between the duration until 
termination of PE or GH and maternal kidney function 
was not significantly (Fig. 2).
We next focused on the GH patients and high UA 
levels (Table 3).  The onset of GH in patients with nor-
mal UA levels was significantly earlier than the onset in 
the GH patients with high UA levels (p = 0.02).  
However,  the duration until termination in patients 
with high UA levels was significantly earlier compared 
to those with normal UA levels (p = 0.04).  Among the 
patients with GH and high UA levels,  3 patients had 
hemolysis,  elevated liver enzymes,  and low platelets 
(HELLP) syndrome,  1 had placental abruption,  and 4 
had non-reassuring fetal status.  The rate of HELLP syn-
drome among the patients with both GH and high UA 
levels was significantly higher than the rate of patients 
with GH and normal UA levels.  Five other patients 
with high UA levels had an arrest of fetal development 
and elevation of blood pressure,  and their pregnancies 
were terminated as soon as possible (Table 3).
We divided the 21 patients with both GH and high 
UA levels into 2 groups: those with SGA infants and 
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Fig. 2　 Association between the duration until termination of preeclampsia or gestational hypertension and maternal kidney function.
those with appropriate-for-gestational age neonates.  
Between these 2 groups,  there were significant differ-
ences in the number of gestational weeks at delivery 
(p = 0.04),  the onset of GH (p = 0.0006),  the duration 
until termination (p = 0.02),  and placental weight 
(p = 0.0001,  Table 4).  One of the 5 patients with SGA 
infants had HELLP syndrome,  one had placental 
abruption,  and the other 2 patients had non-reassuring 
fetal status.
Discussion
Our study showed that the mean values of maternal 
age,  gestational age at delivery,  placental weight,  birth 
weight,  and height of neonates in the cases of PE were 
significantly greater than those in the cases of GH.  
Several studies have reported that PE is associated with 
maternal and perinatal poor outcomes,  which is consis-
tent with our present findings.  Barton et al.  reported 
that gestational age of the infants at delivery,  birth 
weight,  incidence of SGA newborns differed signifi-
cantly in PE with versus those in GH [7].  Other studies 
reported that the birth weights in PE cases were lower 
than those of controls,  but those in GH cases were not 
significantly different from the controls [8 , 9].  In 
another investigation,  the number of gestational weeks 
and birth weight in PE cases were less than those in GH 
(not significant),  and those in PE and GH cases 
together were significantly less than those of controls 
[10].  These studies suggest that there is a marked dif-
ference in fetal growth between GH and PE cases.
A pregnancy with PE is terminated at an early gesta-
tional age [7-10].  Xiong et al.  reported that perinatal 
mortality and fetal growth restriction (FGR) were 
increased the most in GH cases,  followed by PE cases,  
and then severe PE cases [11].  Our analysis of the cir-
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Table 4　 Comparison of patients with gestational hypertension (GH) who had small-for-gestational age (SGA) infants and those who had 
appropriate-for-gestational age (AGA) infants
SGA AGA p
High UA levels
n＝5 n＝16
Gestational age at delivery (wks) 35.6±2.5 38.9±1.9 0.04
Onset of GH (wks) 33.6±2.5 38.3±2.2 0.0006
Duration until termination (wks) 2.0±2.0 0.6±0.7 0.02
Placenta weight (g) 386±43.1 561±80.4 0.0001
Caesarean section (person) 3 (60%) 5 (31%) 0.24
Normal UA
levels
n＝2 n＝26
Gestational age at delivery (wks) 35.5±3.5 37.5±1.9 0.1
Onset of GH (wks) 31±8.4 34.5±4.7 0.3
Duration until termination (wks) 2.0±4.9 3.0±4.5 0.6
Placenta weight (g) 293±118 500±138 0.05
Caesarean section (person) 1 (50%) 11 (42%) 0.8
Table 3　 Comparison of patients with high uric acid (UA) levels and those with normal uric acid levels in gestational hypertension
High UA (n＝21) Normal UA (n＝28) p
Infant birth weight percentile 37.6±30.3 40.7±33.3 0.74
Gestational age at delivery (wks) 38.1±2.5 37.4±2.1 0.23
The onset of GH (wks) 37.2±3.0 34.3±5.0 0.02
Duration until termination(wks) 1.0±1.2 3.1±4.5 0.04
Placenta weight (g) 519±105 486±145 0.37
Ratio of severe hypertension (%) 52 29 0.09
Emergency caesarean section（person） 7 (33%) 7 (25%) 0.16
Placental abruption（person） 1 (5%) 4 (14%) 0.27
HELLP syndrome（person） 3 (14%) 0 (0%) 0.03
NRFS (person) 4 (19%) 5 (18%) 0.91
NRFS,  non-reassuring fetal status; UA,  uric acid; GH,  gestational hypertension.
cumferences of the chest/head indicated that newborns 
born to mothers with PE may have asymmetrical FGR.  
It is likely that PE leads to asymmetrical FGR based on 
pathological factors.  Because of these maternal and 
perinatal differences,  we conclude that GH is different 
from PE.
Additionally,  our study showed that parameters of 
kidney function (i.e.,  UA levels,  creatinine levels,  and 
eGFR) were correlated with each other,  and that the 
kidney function of the patients with GH was similar to 
that of the patients with PE.  We divided the GH and PE 
cases by the difference in proteinuria,  but there was no 
significant difference in the kidney function.  Our find-
ings also showed that birth weight was correlated with 
kidney function only in the cases of PE.  However,  the 
kidney function in the PE and GH groups was not cor-
related with severe hypertension or the duration until 
termination of PE and GH.  Therefore,  abnormal kid-
ney function is a high risk of FGR in PE,  but not in 
GH.
Several studies have noted that kidney function plays 
a major role in hypertensive disorders.  An example of 
this is that UA levels are related to the onset of essential 
hypertension in children [12].  It has also been reported 
that UA levels are related to PE.  In a study,  plasma UA 
levels predicted fetal death in hypertensive pregnancies 
[13].  Pramanik et al.  reported higher UA levels and 
higher blood pressure in PE during pregnancy com-
pared to normal pregnancy [14].
Other investigations have shown that UA levels were 
altered at the initial stages of PE [15] and that UA levels 
were associated with maternal and perinatal outcomes 
in PE [16].  Additionally,  kidney function is correlated 
with fetal growth.  UA and creatinine levels are cor-
related with fetal growth in normotensive pregnant 
women [17 , 18].  Moreover,  it was reported that UA 
levels were predictive of perinatal outcomes but not 
maternal outcomes in PE [19] and that UA levels were 
correlated with low birth weight [15].
From a pathological point of view,  UA plays a role in 
inflammation,  oxidative stress,  and endothelial dys-
function.  These situations might affect the develop-
ment of a small placenta [20],  which in turn affects fetal 
growth.  High UA levels in PE may promote inflamma-
tion,  oxidative stress and endothelial dysfunction,  and 
then the placenta becomes small because of poor vascu-
lar remodeling of the placental bed [21].  A small pla-
centa leads to SGA and other perinatal complications 
[22 , 23].
In our study,  the placenta in the patients with PE 
was smaller compared to the GH cases.  The measure-
ment of kidney function (such as UA levels) might pre-
dict FGR in patients with PE or PE in patients with 
FGR.  We found that the UA levels in the patients with 
PE were higher than those in the patients with GH,  but 
the difference was not significant.  Our analysis demon-
strated that kidney function was correlated with birth 
weight only in PE.  These findings suggest that a high 
level of UA is a prognostic factor for FGR in PE.
In our GH patient series,  the onset of GH,  the 
duration until termination,  and HELLP syndrome in 
the patients with high UA levels were significantly dif-
ferent from those in the patients with normal UA levels.  
Although the onset of GH in the patients with high UA 
levels was significantly later compared to those with 
normal UA levels,  the patients with high UA levels 
showed a shorter duration until termination,  which 
indicates that their symptoms became worse rapidly.  
Many of our patients with high UA levels delivered at 
full term.  Therefore,  a short period to termination did 
not influence fetal growth.
Several research groups have suggested that GH with 
hyperuricemia is a perinatal risk.  A case-control study 
reported that hyperuricemia with GH increased the 
risks of preterm labor and FGR,  and these patients had 
similar or greater risks than those with PE [24].  Some 
studies have indicated that HELLP syndrome is associ-
ated with the endothelial factor,  similar to a small pla-
centa with a high UA level in PE [25 , 26].  In our study,  
the patients with both GH and high UA levels with SGA 
infants showed a significant difference in the number of 
gestational weeks at delivery,  the onset of GH,  the 
duration until termination,  and placental weight com-
pared to the patients with GH and high UA levels with-
out SGA infants.
The patients with GH,  normal UA levels and SGA 
infants did not show a significant difference compared 
with those with GH and normal UA levels without SGA 
infants.  Additionally,  the maternal and perinatal out-
comes of the patients with GH and high UA levels with 
SGA infants were extremely high-risk.  We consider that 
these patients could develop PE,  or the pathological 
state may be similar to PE.  Schmella et al.  reported that 
hyperuricemia is predictive of a high risk of GH,  simi-
lar to proteinuria [27].  Therefore,  we consider that GH 
is a mixture of former PE and pure GH.
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UA affects essential hypertension in children [12].  A 
brief review showed that there is a pathogenetic role for 
UA in not only hypertension,  but also in cardiovascular 
and renal disease [28].  The follow-up of UA levels after 
pregnancy might thus be important for the prediction 
of cardiovascular or metabolic syndrome in the mother 
and child later in life.
This study excludes the superimposed preeclampsia 
and eclampsia at first,  but includes the case with mater-
nal complications such as diabetes mellitus.  We will 
investigate the cases of PE and GH associated with no 
maternal complications in the future.  The limitations of 
this study are (1) the relatively small number of patients,  
(2) the many patients who showed normal progress did 
not have all data available,  and (3) kidney function was 
not continuously measured.  We need to analyze UA 
levels continuously during pregnancy to determine 
when UA levels become high.  UA levels increase at 
approx.  20 weeks of gestation in pregnancies with PE 
[15].  We believe that UA levels need to be measured at 
least before pregnancy and after 20 weeks of gestation.
A determination of the predictability of PE and GH 
is important for clinical treatments,  especially for con-
trolling severe hypertensive disorders,  termination in 
the early gestational weeks,  and determining maternal 
and perinatal outcomes.  PE cases reached termination 
at an early point because the onset of PE was early and 
then proteinuria,  kidney function,  and maternal and 
neonatal outcomes are worsen.  In contrast,  because the 
onset of GH was late,  GH cases reached the point of 
delivery before the appearance of proteinuria.  But in the 
case such as GH with SGA,  the onset was early,  these 
cases were terminated in the early gestational weeks,  
and maternal and neonatal outcomes turned worse like 
PE.
Although GH is generally milder than PE,  perinatal 
outcomes are worse if UA levels are high.  Patients with 
GH and high UA levels must be more carefully man-
aged.  We believe that kidney function plays an import-
ant role in fetal growth and in the severity of PE cases 
and GH cases that are similar to PE.  Cases of GH may 
actually be PE because of high UA levels,  FGR,  or in 
the most severe cases both high UA and FGR.  
Consequently,  monitoring of kidney function by blood 
tests in PE and GH patients is important.
In conclusion,  patients with GH and high UA levels,  
especially those with SGA infants,  have perinatal out-
comes similar to those with PE.  The monitoring of 
kidney function is an important examination during 
pregnancy to determine the severity of GH or PE.
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